{
  "analysis_mode": "HISTORICAL_ONLY",
  "symbol": "TRLS.L",
  "generated_at": "2026-01-21T22:42:58.015783Z",
  "top_card": {
    "ticker": "TRLS.L",
    "company_name": "Trellus Health plc",
    "sector": "Healthcare",
    "market_cap_gbp": 2786018,
    "days_active": 19,
    "apex_score_100": 57,
    "confidence_score_100": 60,
    "ai_final_score_25": 11,
    "ai_strength": "MODERATE",
    "timing_regime": "EARLY_BUILD",
    "action": "WATCH",
    "thesis_one_liner": "WATCH - EARLY_BUILD timing with 57/100 opportunity score"
  },
  "enrichment": {
    "company_info": {
      "name": "Trellus Health plc",
      "sector": "Healthcare",
      "industry": "Health Information Services",
      "exchange": "LSE",
      "market": "AIM",
      "currency": "GBP",
      "risk_tier": "High Risk",
      "current_market_cap": 2786018,
      "current_close_price": 1.2
    },
    "basics": {
      "ticker": "TRLS.L",
      "current_price": 1.2,
      "ath": 78.0,
      "atl": 0.301,
      "ath_date": "2021-06-15",
      "atl_date": "2025-12-31",
      "week_52_high": 3.2,
      "week_52_low": 0.301,
      "week_52_high_date": "2025-01-27",
      "week_52_low_date": "2025-12-31",
      "drawdown_from_ath_pct": 98.46,
      "data_start": "2021-05-28",
      "data_end": "2026-01-21",
      "total_bars": 1174
    },
    "latest_signal": {
      "date": "2026-01-02",
      "scan_date": "2026-01-14",
      "signal_type": "CRASH ZONE BOTTOM",
      "signal_color": "YELLOW",
      "price": 0.4,
      "drawdown_pct": 92.59,
      "ai_score": 9.0,
      "rsi": 12.5,
      "cycle_position": 0.1984,
      "holding_period_days": 19,
      "current_pnl_pct": 200.0,
      "rally_state": "pulling_back",
      "distance_from_high_pct": -28.36,
      "Rally_Count": 1,
      "days_since_last_high": 9,
      "last_high_date": "2026-01-12",
      "lock_in_reached": true,
      "lock_in_date": "2026-01-20",
      "best_rally_pct": 318.75
    },
    "best_historical_signal": {
      "signal_date": "2024-11-28",
      "signal_type": "DEEP CRASH BOTTOM",
      "signal_color": "GREEN",
      "entry_price": 0.625,
      "peak_price": 5.4,
      "peak_date": "2025-01-15",
      "rally_pct": 764.0,
      "days_to_peak": 48,
      "ai_score": 11.0
    },
    "all_historical_signals": [
      {
        "signal_id": "TRLS.L_2022-06-29",
        "signal_date": "2022-06-29",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 14.0,
        "current_price": 0.35,
        "current_return_pct": -97.5,
        "best_rally_pct": 0.0,
        "best_rally_date": "2022-06-30",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 1295,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2022-07-01",
        "signal_date": "2022-07-01",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 13.25,
        "current_price": 0.35,
        "current_return_pct": -97.36,
        "best_rally_pct": 1.89,
        "best_rally_date": "2022-10-06",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -97.41,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 1293,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2022-07-04",
        "signal_date": "2022-07-04",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 13.25,
        "current_price": 0.35,
        "current_return_pct": -97.36,
        "best_rally_pct": 1.89,
        "best_rally_date": "2022-10-06",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -97.41,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 1290,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2022-07-05",
        "signal_date": "2022-07-05",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 13.25,
        "current_price": 0.35,
        "current_return_pct": -97.36,
        "best_rally_pct": 1.89,
        "best_rally_date": "2022-10-06",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -97.41,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 1289,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2022-07-06",
        "signal_date": "2022-07-06",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 11.5,
        "current_price": 0.35,
        "current_return_pct": -96.96,
        "best_rally_pct": 17.39,
        "best_rally_date": "2022-10-06",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -97.41,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 1288,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2022-07-08",
        "signal_date": "2022-07-08",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 10.75,
        "current_price": 0.35,
        "current_return_pct": -96.74,
        "best_rally_pct": 25.58,
        "best_rally_date": "2022-10-06",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -97.41,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 1286,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2022-07-12",
        "signal_date": "2022-07-12",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 10.25,
        "current_price": 0.35,
        "current_return_pct": -96.59,
        "best_rally_pct": 31.71,
        "best_rally_date": "2022-10-06",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -97.41,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 1282,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2022-07-27",
        "signal_date": "2022-07-27",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 8.0,
        "current_price": 0.35,
        "current_return_pct": -95.63,
        "best_rally_pct": 68.75,
        "best_rally_date": "2022-10-06",
        "rally_state": "accumulating",
        "Rally_Count": 4,
        "distance_from_high_pct": -97.41,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 1267,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2022-07-28",
        "signal_date": "2022-07-28",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 9.0,
        "current_price": 0.35,
        "current_return_pct": -96.11,
        "best_rally_pct": 50.0,
        "best_rally_date": "2022-10-06",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -97.41,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 1266,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2022-07-29",
        "signal_date": "2022-07-29",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 9.0,
        "current_price": 0.35,
        "current_return_pct": -96.11,
        "best_rally_pct": 50.0,
        "best_rally_date": "2022-10-06",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -97.41,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 1265,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2022-08-19",
        "signal_date": "2022-08-19",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 7.5,
        "current_price": 0.35,
        "current_return_pct": -95.33,
        "best_rally_pct": 80.0,
        "best_rally_date": "2022-10-06",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -97.41,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 1244,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2022-08-24",
        "signal_date": "2022-08-24",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.25,
        "current_price": 0.35,
        "current_return_pct": -95.17,
        "best_rally_pct": 86.21,
        "best_rally_date": "2022-10-06",
        "rally_state": "accumulating",
        "Rally_Count": 4,
        "distance_from_high_pct": -97.41,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 1239,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2022-08-25",
        "signal_date": "2022-08-25",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 7.25,
        "current_price": 0.35,
        "current_return_pct": -95.17,
        "best_rally_pct": 86.21,
        "best_rally_date": "2022-10-06",
        "rally_state": "accumulating",
        "Rally_Count": 4,
        "distance_from_high_pct": -97.41,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 1238,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2022-08-26",
        "signal_date": "2022-08-26",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.25,
        "current_price": 0.35,
        "current_return_pct": -95.17,
        "best_rally_pct": 86.21,
        "best_rally_date": "2022-10-06",
        "rally_state": "accumulating",
        "Rally_Count": 4,
        "distance_from_high_pct": -97.41,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 1237,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2022-09-26",
        "signal_date": "2022-09-26",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 7.129,
        "current_price": 0.35,
        "current_return_pct": -95.09,
        "best_rally_pct": 89.37,
        "best_rally_date": "2022-10-06",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -97.41,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 1206,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2022-09-30",
        "signal_date": "2022-09-30",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 7.25,
        "current_price": 0.35,
        "current_return_pct": -95.17,
        "best_rally_pct": 86.21,
        "best_rally_date": "2022-10-06",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -97.41,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 1202,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2023-01-17",
        "signal_date": "2023-01-17",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 9.25,
        "current_price": 0.35,
        "current_return_pct": -96.22,
        "best_rally_pct": -0.54,
        "best_rally_date": "2023-09-20",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 1093,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2023-01-18",
        "signal_date": "2023-01-18",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 8.85,
        "current_price": 0.35,
        "current_return_pct": -96.05,
        "best_rally_pct": 3.95,
        "best_rally_date": "2023-09-20",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -96.2,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 1092,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2023-02-14",
        "signal_date": "2023-02-14",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 7.5,
        "current_price": 0.35,
        "current_return_pct": -95.33,
        "best_rally_pct": 22.67,
        "best_rally_date": "2023-09-20",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -96.2,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 1065,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2024-04-16",
        "signal_date": "2024-04-16",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.75,
        "current_price": 0.35,
        "current_return_pct": -80.0,
        "best_rally_pct": 182.86,
        "best_rally_date": "2025-01-14",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -92.93,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 638,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2024-05-24",
        "signal_date": "2024-05-24",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 1.65,
        "current_price": 0.35,
        "current_return_pct": -78.79,
        "best_rally_pct": 200.0,
        "best_rally_date": "2025-01-14",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -92.93,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 600,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2024-05-30",
        "signal_date": "2024-05-30",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.45,
        "current_price": 0.35,
        "current_return_pct": -75.86,
        "best_rally_pct": 241.38,
        "best_rally_date": "2025-01-14",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -92.93,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 594,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2024-06-03",
        "signal_date": "2024-06-03",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.45,
        "current_price": 0.35,
        "current_return_pct": -75.86,
        "best_rally_pct": 241.38,
        "best_rally_date": "2025-01-14",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -92.93,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 590,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2024-06-17",
        "signal_date": "2024-06-17",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.4,
        "current_price": 0.35,
        "current_return_pct": -75.0,
        "best_rally_pct": 253.57,
        "best_rally_date": "2025-01-14",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -92.93,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 576,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2024-06-18",
        "signal_date": "2024-06-18",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.3,
        "current_price": 0.35,
        "current_return_pct": -73.08,
        "best_rally_pct": 280.77,
        "best_rally_date": "2025-01-14",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -92.93,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 575,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2024-08-09",
        "signal_date": "2024-08-09",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.25,
        "current_price": 0.35,
        "current_return_pct": -72.0,
        "best_rally_pct": 296.0,
        "best_rally_date": "2025-01-14",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -92.93,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 523,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2024-08-12",
        "signal_date": "2024-08-12",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.3,
        "current_price": 0.35,
        "current_return_pct": -73.08,
        "best_rally_pct": 280.77,
        "best_rally_date": "2025-01-14",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -92.93,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 520,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2024-08-16",
        "signal_date": "2024-08-16",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.25,
        "current_price": 0.35,
        "current_return_pct": -72.0,
        "best_rally_pct": 296.0,
        "best_rally_date": "2025-01-14",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -92.93,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 516,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2024-08-20",
        "signal_date": "2024-08-20",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.15,
        "current_price": 0.35,
        "current_return_pct": -69.57,
        "best_rally_pct": 330.43,
        "best_rally_date": "2025-01-14",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -92.93,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 512,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2024-08-27",
        "signal_date": "2024-08-27",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.1,
        "current_price": 0.35,
        "current_return_pct": -68.18,
        "best_rally_pct": 350.0,
        "best_rally_date": "2025-01-14",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -92.93,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 505,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2024-09-26",
        "signal_date": "2024-09-26",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 1.05,
        "current_price": 0.35,
        "current_return_pct": -66.67,
        "best_rally_pct": 371.43,
        "best_rally_date": "2025-01-14",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -92.93,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 475,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2024-10-17",
        "signal_date": "2024-10-17",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.63,
        "current_price": 0.35,
        "current_return_pct": -44.44,
        "best_rally_pct": 685.71,
        "best_rally_date": "2025-01-14",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -92.93,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 454,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2024-10-29",
        "signal_date": "2024-10-29",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.675,
        "current_price": 0.35,
        "current_return_pct": -48.15,
        "best_rally_pct": 633.33,
        "best_rally_date": "2025-01-14",
        "rally_state": "accumulating",
        "Rally_Count": 4,
        "distance_from_high_pct": -92.93,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 442,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2024-11-28",
        "signal_date": "2024-11-28",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.625,
        "current_price": 0.35,
        "current_return_pct": -44.0,
        "best_rally_pct": 692.0,
        "best_rally_date": "2025-01-14",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -92.93,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 412,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2024-11-29",
        "signal_date": "2024-11-29",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.625,
        "current_price": 0.35,
        "current_return_pct": -44.0,
        "best_rally_pct": 692.0,
        "best_rally_date": "2025-01-14",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -92.93,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 411,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2024-12-03",
        "signal_date": "2024-12-03",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.625,
        "current_price": 0.35,
        "current_return_pct": -44.0,
        "best_rally_pct": 692.0,
        "best_rally_date": "2025-01-14",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -92.93,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 407,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2025-06-09",
        "signal_date": "2025-06-09",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.95,
        "current_price": 0.35,
        "current_return_pct": -63.16,
        "best_rally_pct": 15.79,
        "best_rally_date": "2025-08-08",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -68.18,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 219,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2025-06-10",
        "signal_date": "2025-06-10",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.9,
        "current_price": 0.35,
        "current_return_pct": -61.11,
        "best_rally_pct": 22.22,
        "best_rally_date": "2025-08-08",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -68.18,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 218,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2025-06-24",
        "signal_date": "2025-06-24",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.625,
        "current_price": 0.35,
        "current_return_pct": -44.0,
        "best_rally_pct": 76.0,
        "best_rally_date": "2025-08-08",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -68.18,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 204,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2025-06-25",
        "signal_date": "2025-06-25",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.65,
        "current_price": 0.35,
        "current_return_pct": -46.15,
        "best_rally_pct": 69.23,
        "best_rally_date": "2025-08-08",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -68.18,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 203,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2025-07-09",
        "signal_date": "2025-07-09",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.65,
        "current_price": 0.35,
        "current_return_pct": -46.15,
        "best_rally_pct": 69.23,
        "best_rally_date": "2025-08-08",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -68.18,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 189,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2025-07-22",
        "signal_date": "2025-07-22",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.6,
        "current_price": 0.35,
        "current_return_pct": -41.67,
        "best_rally_pct": 83.33,
        "best_rally_date": "2025-08-08",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -68.18,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 176,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2025-09-08",
        "signal_date": "2025-09-08",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.5,
        "current_price": 0.35,
        "current_return_pct": -30.0,
        "best_rally_pct": 70.0,
        "best_rally_date": "2025-10-10",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -58.82,
        "days_since_last_high": 15,
        "lock_in_reached": true,
        "age_days": 128,
        "status": "historical"
      },
      {
        "signal_id": "TRLS.L_2025-11-20",
        "signal_date": "2025-11-20",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.525,
        "current_price": 0.4,
        "current_return_pct": -23.81,
        "best_rally_pct": 23.81,
        "best_rally_date": "2025-11-24",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -38.46,
        "days_since_last_high": 8,
        "lock_in_reached": true,
        "age_days": 58,
        "status": "active"
      },
      {
        "signal_id": "TRLS.L_2025-12-31",
        "signal_date": "2025-12-31",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.375,
        "current_price": 1.2,
        "current_return_pct": 220.0,
        "best_rally_pct": 346.67,
        "best_rally_date": "2026-01-20",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -28.36,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 21,
        "status": "active"
      },
      {
        "signal_id": "TRLS.L_2026-01-02",
        "signal_date": "2026-01-02",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.4,
        "current_price": 1.2,
        "current_return_pct": 200.0,
        "best_rally_pct": 318.75,
        "best_rally_date": "2026-01-20",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -28.36,
        "days_since_last_high": 9,
        "lock_in_reached": true,
        "age_days": 19,
        "status": "active"
      }
    ],
    "stats": {
      "total_signals": 46,
      "win_rate_pct": 100.0,
      "avg_rally_pct": 253.38,
      "median_rally_pct": 243.33,
      "best_rally_pct": 764.0,
      "worst_rally_pct": 4.32
    },
    "splits": [],
    "split_risk": {
      "split_detected": false,
      "risk_level": "NONE",
      "confidence": "HIGH"
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [
      "EXTREME_DRAWDOWN",
      "FREQUENT_CRASHES"
    ],
    "last_updated": "2026-01-21 22:05:58 UTC",
    "volatility": {
      "atr_normalized": 8.75,
      "stddev_20d": 0.0
    },
    "trends": {
      "intelligence_signal": "DOWNTREND"
    }
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 57/100 indicates strong opportunity quality",
      "Timing regime: EARLY_BUILD",
      "Historical profile: 1 rallies, 319% best run"
    ],
    "main_risk": "Confidence 60/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "TRLS.L",
      "latest": [
        {
          "title": "Result of Meeting",
          "announcement_date": "20th Jan 2026",
          "release_time": "2:00 pm",
          "source": "RNS",
          "content": "20 Jan 2026 14:00\nRNS Number : 6378P\nTrellus Health PLC\n20 January 2026\nTrellus Health plc\n(\"Trellus Health\", the \"Company\" or the \"Group\")\nResult of General Meeting\nLONDON, U.K. AND NEW YORK, U.S. (20 January 2026).\nTrellus Health\n\u00ae\nplc (AIM: TRLS), a healthcare company delivering Trellus Elevate\n\u00ae\n, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces that at the General Meeting (\"GM\") held earlier today, all resolutions, as set out in the GM notice published on 31 December 2025, were duly passed on a poll.\nThe voting results of the GM were as follows:\nIn Favour\nAgainst\nWithheld\nResolution\nType\nVotes\n%\nVotes\n%\nVotes\n1\nOrdinary\n68,221,782\n99.90\n71,031\n0.10\n4,625\n2\nSpecial\n68,217,291\n99.89\n76,004\n0.11\n4,143\n3\nOrdinary\n68,221,782\n99.90\n71,031\n0.10\n4,625\n4\nSpecial\n68,206,212\n99.87\n87,083\n0.13\n4,143\n5\nSpecial\n68,206,212\n99.87\n87,083\n0.13\n4,143\nFor further information please contact:\nTrellus Health plc\nhttps://trellushealth.com/\nDr. Marla Dubinsky, Chief Executive Officer and Co-Founder\nVia Walbrook PR\nJoy Bessenger, Chief Financial Officer\nSinger Capital Markets (Nominated Adviser and Broker)\nTel: +44 (0)20 7496 3000\nPhilip Davies / James Todd / Patrick Weaver\nWalbrook PR\nTel: +44 (0)20 7933 8780\nor\ntrellus@walbrookpr.com\nPaul McManus / Lianne Applegarth /\nAlice Woodings\nMob: +44 (0)7980 541 893 /\n+44 (0)7584 391 303/\n+44 (0)7407 804 654\nAbout Trellus Health plc (\nwww.trellushealth.com\n)\nTrellus Health\n\u00ae\n(AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.\nTrellus Health integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate\n\u00ae\n, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying Trellus Elevate resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions, Trellus Health considers its approach to have potential utility and demand across many conditions.\nTrellus Health\nalso offers a seamless solution for pharmaceutical partners from clinical trials to commercialisation, harnessing resilience-based methods to drive both trial and patient support success by empowering patients to stay engaged, adhere to their treatment, and manage their health confidently.\nThe Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, both world-leading experts at treating and healing both the physical and emotional impacts of IBD and have been innovators for whole-person healthcare for a combined 50 years.\nShares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit:\nwww.trellushealth.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nROMXBLFLQFLZBBE",
          "rns_number": "RNS Number : 6378P"
        },
        {
          "title": "Grant of Share Options",
          "announcement_date": "19th Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "19 Jan 2026 07:00\nRNS Number : 3331P\nTrellus Health PLC\n19 January 2026\nTrellus Health plc\n(\"Trellus Health\", the \"Company\" or the \"Group\")\nGrant of Share Options\nLONDON, U.K. AND NEW YORK, U.S. (19 January 2026).\nTrellus Health\n\u00ae\nplc (AIM: TRLS), a healthcare company delivering Trellus Elevate\n\u00ae\n, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces that the Board has granted options over a total of 807,541 ordinary shares of \u00a30.0006 in the capital of the Company (the \"Share Options\") to Kevin Murphy, Chairman of the Company (the \"Option Holder\").\nThe Share Options, which have been issued in line with the Company's existing share option plan (the \"Option Plan\"), have an exercise price of 0.525p per ordinary share. This is in line with the exercise price of the Loan Note, entered into with Mount Sinai on November 24, 2025. The Share Options are subject to lock-in provisions, being 12 months from the date the Share Options are exercised.\nThe Share Options vest and become exercisable in twelve (12) equal quarterly instalments (rounded up to the nearest whole share) thereafter of which the first instalment shall vest three months after the grant date and the twelfth shall vest 39 months after the vesting commencement date.\nThe Share Options are subject to the rules of the Option Plan and the relevant award documentation, including customary good leaver and bad leaver provisions.\nThe independent directors consider that the award is fair and reasonable insofar as the Company's shareholders are concerned and believe it appropriately aligns the Chairman's interests with those of shareholders.\nCapitalised terms used but not otherwise defined in this announcement shall have the meanings given to them in the Company's announcement released on 30 December 2025.\nFor further information please contact:\nTrellus Health plc\nhttps://trellushealth.com/\nDr. Marla Dubinsky, Chief Executive Officer and Co-Founder\nVia Walbrook PR\nJoy Bessenger, Chief Financial Officer\nSinger Capital Markets (Nominated Adviser and Broker)\nTel: +44 (0)20 7496 3000\nPhilip Davies / James Todd / Patrick Weaver\nWalbrook PR\nTel: +44 (0)20 7933 8780\nor\ntrellus@walbrookpr.com\nPaul McManus / Lianne Applegarth /\nAlice Woodings\nMob: +44 (0)7980 541 893 /\n+44 (0)7584 391 303/\n+44 (0)7407 804 654\nAbout Trellus Health plc (\nwww.trellushealth.com\n)\nTrellus Health\n\u00ae\n(AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.\nTrellus Health integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate\n\u00ae\n, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying Trellus Elevate resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions, Trellus Health considers its approach to have potential utility and demand across many conditions.\nTrellus Health\nalso offers a seamless solution for pharmaceutical partners from clinical trials to commercialisation, harnessing resilience-based methods to drive both trial and patient support success by empowering patients to stay engaged, adhere to their treatment, and manage their health confidently.\nThe Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, both world-leading experts at treating and healing both the physical and emotional impacts of IBD and have been innovators for whole-person healthcare for a combined 50 years.\nShares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit:\nwww.trellushealth.com\n1\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\nKevin Laurence Murphy\n2\nReason for the notification\na)\nPosition/status\nChairman\nb)\nInitial notification /Amendment\nInitial notification\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nTrellus Health plc\nb)\nLEI\n2138002FHWJSR8YKP295\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the financial instrument, type of instrument\nOptions over ordinary shares of \u00a30.0006 each in the Company\nIdentification code\nGB00BNNFM402\nb)\nNature of the transaction\nGrant of options over shares\nc)\nPrice(s) and volume(s)\nPrice(s)\nVolume(s)\n\u00a30.00525 exercise price\n807,541\nd)\nAggregated information\n- Aggregated volume\nN/A\n- Price\nN/A\ne)\nDate of the transaction\n16\nJanuary 2026\nf)\nPlace of the transaction\nOutside of trading venue - off market\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nDSHBPMBTMTBBTJF",
          "rns_number": "RNS Number : 3331P"
        },
        {
          "title": "Proposed issue of Secured Convertible Loan Notes",
          "announcement_date": "30th Dec 2025",
          "release_time": "5:00 pm",
          "source": "RNS",
          "content": "30 Dec 2025 17:00\nRNS Number : 1958N\nTrellus Health PLC\n30 December 2025\nTHIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO PURCHASE AND/OR SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN TRELLUS HEALTH PLC OR ANY OTHER ENTITY IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR THE FACT OF ITS DISTRIBUTION, SHALL FORM THE BASIS OF, OR BE RELIED ON IN CONNECTION WITH ANY INVESTMENT DECISION IN RESPECT OF TRELLUS HEALTH PLC OR ANY OTHER ENTITY.\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION RELATING TO TRELLUS HEALTH PLC AND ITS SECURITIES FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (596/2014/EU) AS IT FORMS PART OF THE DOMESTIC LAW OF THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (\"EUWA\") AND AS MODIFIED BY OR UNDER THE EUWA OR OTHER DOMESTIC LAW, INCLUDING BUT NOT LIMITED TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) (\"UK MAR\"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR), AS PERMITTED BY UK MAR. THIS INSIDE INFORMATION IS SET OUT IN THIS ANNOUNCEMENT. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION RELATING TO TRELLUS HEALTH PLC AND ITS SECURITIES, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\nTrellus Health plc\n(\"\nTrellus Health\n\" or the \"\nCompany\n\")\nProposed issue of Secured Convertible Loan Notes to raise up to \u00a35 million\nand grant of Warrants\nDefinitions contained within Appendix I to this Announcement apply, unless the context requires otherwise\nTrellus Health plc (AIM: TRLS), a healthcare company delivering Trellus Elevate\u00ae, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces that it proposes to issue \u00a35 million Secured Convertible Loan Notes (the Facility) to an institutional investor to extend the Company's cash runway, subject to Shareholder approval. The Company had previously announced that it had entered into an unsecured loan agreement with its long-standing substantial shareholder, Mount Sinai, with a principal amount of US$600,000 which\nsupported the continued execution of the Company's commercial strategy and extend its near-term cash runway to late January 2026. Since this time, the Company has been in active discussions with the aim of securing additional funds to extend the cash runway further, hence the\nSecured Convertible Loan Notes.\nThe Facility is structured to provide Trellus Health with flexible, staged access to capital to support its operational and commercial objectives, while managing dilution and aligning funding availability with execution milestones.\nKey features include:\n\u00b7\n12 month facility of up to \u00a35 million in principal, available in multiple tranches;\n\u00b7\nconversion at a discount to market price at the time of conversion, with tranche-specific terms; and\n\u00b7\nwarrant coverage issued in connection with each tranche.\nFurther details of the Facility are set out below and in the Circular, which is to be posted to Shareholders tomorrow and will be made available on the Company's website at\ntrellushealth.com/investors\n.\nThe Board believes that the Facility:\n\u00b7\nstrengthens the Company's near-term funding position while preserving flexibility over the timing and scale of capital drawdowns;\n\u00b7\nenables the Company to align conversions with market conditions;\n\u00b7\nsupports the Company's ongoing commercial initiatives and partnership discussions; and\n\u00b7\nreflects continued access to institutional capital from a financial investor familiar with structured growth financing.\nThe Directors also consider the inclusion of warrant coverage (details of which are provided below) provides additional alignment between investor returns and the longer-term performance of the Company, while supporting the availability of committed funding. Importantly, the tranche-based structure is intended to allow the Company to manage shareholder dilution and regulatory thresholds while maintaining sufficient working capital to continue to execute its business plan.\nUnder the Facility, the Company may request the drawn down of funds (and Alumni will subscribe for Notes) in the following tranches: first tranche consisting of a principal amount of up to \u00a3112,500 (First Tranche Notes), less fees and agreed deductions, second tranche consisting of a principal amount of up to \u00a3625,000 (Second Tranche Notes) and subsequent tranches each consisting of a principal amount of up to \u00a3200,000 (Subsequent Tranche Notes) subject to certain conditions being satisfied in each case.\nThe Directors believe that the net proceeds of the First Tranche Notes and the Second Tranche Notes (which together total \u00a3737,500 principal gross) will enable the Group to continue in existence until late Q1 2026. Subsequent Tranche Notes may be capable of being drawn but there is no guarantee that this will happen. The Directors are in discussions regarding alternative sources of additional funding to extend the cash runway further, irrespective of the utilisation of the Notes. If Shareholders do not approve the Fundraise Resolutions, the Fundraise will not proceed, with the consequence that the Company would require alternative sources of funding and there can be no guarantee that the Company will be able to find such alternative sources of funding before late January 2026, or at all.\nIf the Fundraise is not capable of proceeding or if it is unsuccessful, it is highly likely that this will result in the Company and the Group not being a going concern and the Directors would be forced to take steps to place the Company into administration.\nThe Directors are of the view that the Fundraise represents the best and only realistic prospect for securing the financing required to meet the Company's working capital requirements and to support its commercialisation strategy.\nThe Directors were granted certain authorities to allot Ordinary Shares for cash and to disapply statutory pre-emption rights at the last annual general meeting of the Company held on 30 June 2025 (Existing Authorities). However, the Existing Authorities are insufficient for the size of the Fundraise and accordingly, the Company is calling the General Meeting, which has been convened for 20 January 2026, to (i) obtain new authorities to issue and allot new Ordinary Shares on a non-pre-emptive basis in respect of the Fundraise (Fundraise Authorities) and (ii) in addition to the Fundraise Authorities, obtain new allotment and dis-application of pre-emption rights authorities in a form similar to the Existing Authorities but calculated by reference to the anticipated Enlarged Share Capital (Standing Authorities).\nThe Fundraise Authorities would authorise the Directors to issue the Secured Convertible Loan Notes. However, the Directors believe it is in the interests of the Company for the Directors to be granted the Standing Authorities, to enable the Directors to take advantage of appropriate opportunities which may arise in the future.\nThe Fundraise is therefore conditional, inter alia, on the passing of the Fundraise Resolutions by Shareholders at the General Meeting, which is to be held at Shoosmiths LLP's London office at 1 Bow Churchyard, London, EC4M 9DQ at 9.30 a.m. on 20 January 2026.\nBackground, to and reasons for, the Fundraise and use of proceeds\nTrellus Health\u00ae is a healthcare company providing innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Founded by Icahn School of Medicine at Mount Sinai faculty members Marla Dubinsky, MD and Laurie Keefer, PhD, globally recognised experts in treating the physical and emotional impacts of Inflammatory\nB\nowel Disease (IBD), with a combined 50 years of pioneering whole-person healthcare innovation.\nThe Company delivers Trellus Elevate\u00ae, a proprietary resilience-based digital platform that combines data analytics, with personalised scientifically proven resilience programs and value-based solutions to help people manage complex chronic conditions. Initially focused on costly gastrointestinal diseases such as IBD, where its methodology has demonstrated over 90% fewer hospitalisations and more than 70% fewer emergency room visits highlighting its role in improving outcomes while reducing healthcare costs\nFrom its founding through 2024, the Company invested approximately $9.6 million in the development and enhancement of the Trellus Elevate\u00ae platform. The platform has been built to scale across multiple chronic conditions and therapeutic areas, integrate within complex and regulated healthcare environments, and support rapid commercial expansion while efficiently leveraging resilience team headcount.\nTrellus Health's business model spans three key verticals: pharmaceutical patient support programs, clinical trial recruitment and retention solutions, and partnerships with US health plans. Through these channels, the Company seeks to improve outcomes, strengthen treatment adherence, and generate meaningful cost savings for healthcare stakeholders.\nIn early 2025, the Company signed a commercial-scale pilot with Johnson & Johnson Health Care Systems Inc. (J&J) to assess the potential for the Trellus Elevate\u00ae program to support patients with moderately to severely active IBD in the US. The program has delivered key early metrics, with 99% patient satisfaction ratings and an average of 50 engagement touchpoints over a 28-day period, supporting plans to broaden enrolment channels beyond the initial narrow funnel.\nIn the second quarter of 2025, the Company renewed its agreement with Pfizer to license patient support educational content for inclusion in Pfizer's IBD digital application. In parallel, Trellus Health\n\u00ae\ncontinues to support an ongoing Phase 2 IBD clinical trial through its licensing agreement with AstraZeneca.\nIn June 2025, Trellus Health\n\u00ae\nwas granted preferred vendor status by a leading global contract research organisation (CRO). As announced on 22 October 2025, the Company subsequently signed a 12-month contract with this CRO to support recruitment and enrolment optimisation for an ongoing mid-stage clinical trial in immunology and inflammation. This program is being implemented on an ongoing basis.\nAdditionally, the Company has been granted preferred vendor status by a second leading global CRO and, as announced on 7 November 2025, signed a 12-month contract to support recruitment and enrolment optimisation for two late-stage clinical trials in immunology and inflammation. The program is also being implemented on an ongoing basis.\nTogether, these partnerships reinforce the value of Trellus Health's offering within the clinical trials vertical, provide access to underlying pharmaceutical clients, and accelerate contracting timelines.\nThe Company's strategy is increasingly focused on expanding its clinical trials business, addressing a well-defined and costly industry challenge. Industry data indicates that more than 50% of clinical trial participants fail screening, contributing to significant delays and inefficiencies in drug development. To address this gap, Trellus Health\n\u00ae\nhas developed Trellus TrialSet\u2122, a solution designed to assess and strengthen participant readiness by ensuring individuals possess the resilience, skills, and tools required to engage, adhere, and persist throughout a trial, thereby optimising recruitment, enrolment, and retention.\nAlongside these growth initiatives, the Company has taken additional cost-containment actions and reduced its average monthly cash burn from approximately $440,000 to $400,000 beginning in November 2025.\nThe Board is focused on driving commercial momentum and expanding the Company's footprint through strategic partnerships particularly within the pharmaceutical verticals. In order to achieve this, the Company requires further investment to extend its cash runway beyond January 2026, allowing time to secure additional commercial contracts. The Company expects that these contracts may take the form of either Pharma Patient Support Programmes (PSPs) or Clinical Trials (CTs) and, with an extended cash runway, is targeting up to 4 new CTs and up to 3 new PSPs, alongside a number of contract expansions over the next two years. Typically, PSPs have an illustrative contract value ranging in total between $500k and $1 million, whilst CTs have an illustrative contract value ranging in total between $150k and $500k excluding performance incentive fees.\nTo support the Company's commercialisation plans, the net proceeds of the Facility would be used by the Company for general working capital purposes, for commercial support and further expansion, technological advancements, specifically in regard to global data privacy (GDPR) and API/white labelling of the platform and intellectual property expansion specifically focused on PSP and CTs. As noted in the 24 November 2025 announcement mentioned above, the Company currently has funds through to the end of January 2026. The Fundraising is required to extend that runway and enable the Company to achieve its commercial objectives together with projected revenues from the new contracts and expansion agreements anticipated to be secured in 2025 and 2026.\nGiven the conversion price of the Notes is determined at the time of conversion notice by reference to a variable rate (as described in more detail at Details of the Fundraise below), the authorities to be granted by the Resolutions have been set at a high level to ensure that the Company has sufficient authorities to complete the Fundraising and such authorities, if granted at the General Meeting, will expire on the date falling 12 months after the passing of the Resolutions at the General Meeting which is to be held at 9.30 a.m. on 20 January 2026 at Shoosmiths LLP's London office at 1 Bow Churchyard, London, EC4M 9DQ.\nCurrent Trading\nThe Company is in the early stages of commercialising its business and, as announced in its interim results on 8 September 2025, generated revenues of $295k in H1 2025 (H1 2024: $114k) and $379k from 1 January to 7 September 2025, related to implementation services and piloting new patients in the Trellus Health platform. The Company's adjusted EBITDA loss for the 6-month period to June 2025 was $2.6m (30 June 2024 $3.6m loss), in line with management expectations. Administrative costs for the first half were $3.3m (30 June 2024: $4.1m). At 30 June 2025, the Group had available cash resources of $1.6m (31 Dec. 2024: $4.3m), with the Company's average monthly burn decreased by an additional c.10% since 1 August 2025 to $440k per month.\nAs announced on 21 October 2025, the Company expects to reduce its average monthly cash burn from approximately $440,000 to around $395,000 going forward. On 24 November 2025, the Company announced that it has signed a $600,000 loan note with Mount Sinai, which extends the Company's runway to the end of January 2026. The Board is pleased with the ongoing commercial progress of the Company and looks forward to providing further updates during Q1 2026.\nDetails of the Fundraise\nThe Company proposes to enter into the Facility and related security agreement (\nDebenture\n) and warrant agreements (\nWarrant Agreements\n) with Alumni whereby the Company shall issue and Alumni shall subscribe for up to a maximum principal amount of \u00a35,000,000 Secured Convertible Loan Notes.\nThe Fundraise is conditional on the passing of the Fundraise Resolutions without material amendment at the General Meeting (or at any adjournment thereof) and the satisfaction of all conditions precedent in the Facility.\nThe key terms of the Facility are as follows:\n1. the Company may request the drawn down of funds (and Alumni will subscribe for Notes) in the following tranches: first tranche consisting of a principal amount of up to \u00a3112,500 (\nFirst Tranche Notes\n), less fees and agreed deductions, second tranche consisting of a principal amount of up to \u00a3625,000 (\nSecond Tranche Notes\n) and subsequent tranches each consisting of a principal amount of up to \u00a3200,000 (\nSubsequent Tranche Notes\n) subject to certain conditions being satisfied in each case. The second tranche may only be drawn down at least 27 business days after closing of the first tranche, and the draw down of the subsequent tranches are conditional on the First Tranche Notes and the Second Tranche Notes being converted to shares. The conditions for each tranche can be waived at Alumni's discretion.\n2. All\noutstanding Notes plus interest will be repayable on the date 12 months from the date of the Facility subject to earlier repayment on the occurrence of market standard events of default or early termination of the Facility or voluntary prepayment(s). In the event of early termination of the Facility, the Company shall pay a 12% premium on any principal amounts (as defined in the Facility) previously drawn and outstanding that have not yet converted into equity.\n3.\nInterest will be payable on the outstanding amount of the Notes subscribed for at the rate of 2.5% per annum. The Company may elect to add such interest to the principal amount of the outstanding Notes.\n4. The\nNotes will be convertible at any time by written notice to the Company at a price per share in GBP equal to (all definitions in (a) - (c) below are as defined in the Facility):\n(a) in\nrespect of the First Tranche Notes, interest on them and Premium Payment (if any), applicable to them, 0.75 multiplied by the lowest daily VWAP of the Shares on the five Trading Days immediately prior to the date of the conversion notice relating to such First Tranche Notes.\n(b)\nin respect of the Second Tranche Notes, interest on them and Premium Payment (if any), applicable to them, 0.55 multiplied by the lowest daily VWAP of the Shares on the five Trading Days immediately prior to the date of the conversion notice relating to such Second Tranche Notes; and\n(c)\nin respect of the Subsequent Tranche Notes (if any), interest on them and Premium Payment (if any), applicable to them, 0.75 multiplied by the lowest daily VWAP of the Shares on the five Trading Days immediately prior to the date of the conversion notice relating to such Subsequent Tranche Notes.\n5.\nThe Notes will be secured by way of the Debenture, which will create fixed and floating charges over all present and future assets and undertaking of the Company subject to prior ranking security interests. The security will be granted in favour of a security trustee to hold the benefit of the security on trust for Alumni and Mount Sinai. Alumni and Mount Sinai will enter into an intercreditor arrangement pursuant to which their interests under the Secured Convertible Loan Note and the Mount Sinai Loan Note (having since been secured) respectively will rank pari passu (\nIntercreditor Deed\n). Draw down of the First Tranche Notes is conditional upon, inter alia, delivery to Alumni of the duly executed Debenture and Intercreditor Deed (both in a form acceptable to Alumni).\n6.\nWith respect to the Warrant Agreements:\n(a) each warrant granted pursuant to each Warrant Agreement (\nWarrant\n) will give its holder a right to subscribe for one Ordinary Share;\n(b)\ncoverage will be 100 per cent of the nominal GBP value of each drawdown, save in relation to the second tranche whereby the coverage will be 130 per cent of the nominal GBP value of the drawdown;\n(c) the exercise price will be 125 per cent of the mid-market price on the business day prior to the execution of the Facility and shall be adjusted upon any dilutive subsequent equity issuance (or equity-linked security) during the term of the relevant Warrant Agreement; and\n(d) the exercise period in respect of each tranche of Warrants will be 4 years from grant.\nTakeover Code\nThere is a limitation that prevents conversion of the Secured Convertible Loan Notes resulting in any shareholder holding over 29.9 per cent of the issued share capital of the Company.\nThe person responsible for arranging the release of this Announcement on behalf of the Company is Dr. Marla Dubinsky, Chief Executive Officer of the Company.\nExpected Timetable of Principal Events\nAnnouncement of the Fundraise\n30 December 2025\nLatest time and date for receipt of proxy votes for the General Meeting\n9.30 a.m. on 16 January 2026\nGeneral Meeting\n9.30 a.m. on 20 January 2026\nAnnouncement of the results of the General Meeting\n20 January 2026\nEach of the times and dates above refer to London time and are subject to change. Certain of the events in the above timetable are conditional upon, inter alia, the passing of the Fundraise Resolutions to be proposed at the General Meeting. If any of the details contained in the timetable above should change, such change will be notified to shareholders by an announcement through a Regulatory Information\u00a0Service.\nEnquiries:\nTrellus Health plc\nhttps://trellushealth.com/\nDr. Marla Dubinsky, Chief Executive Officer and Co-Founder\nVia Walbrook PR\nJoy Bessenger, Chief Financial Officer\nSinger Capital Markets (Nominated Adviser and Broker)\nPhilip Davies / James Todd / Patrick Weaver\nTel: +44 (0)20 7496 3000 303/\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\ntrellus@walbrookpr.com\nPaul McManus / Lianne Applegarth /\nMob: +44 (0)7980 541 893 / +44 (0)7584 391 303/\nAlice Woodings\n+44 (0)7407 804 654\nAbout Trellus Health plc (\nwww.trellushealth.com\n)\nTrellus Health\u00ae (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.\nTrellus Health\u00ae integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate\u00ae, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying the Trellus Elevate\u00ae methodology resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions and therapeutic areas, Trellus Health\u00ae considers its approach to have potential utility and demand across many conditions.\nThe Company also offers Trellus TrialSet\u2122, a solution for pharmaceutical partners spanning clinical trials to commercialisation, applying the same validated resilience science and platform to support trial success and long-term patient engagement\nThe Company was founded by Icahn School of Medicine at Mount Sinai faculty members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading experts in treating both the physical and emotional impacts of IBD, with a combined 50 years of pioneering whole-person healthcare innovation.\nShares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit:\nwww.trellushealth.com\nAPPENDIX I\nDEFINITIONS\nThe following definitions apply\nin the Appendices, and as\nthe context\nshall admit, in the Announcement:\nAIM\nAIM, a\nmarket operated by the London Stock Exchange;\nAIM Rules\nthe AIM Rules for Companies published by the London Stock Exchange\n;\nAlumni:\nAlumni Capital Limited;\nAnnouncement\nthis Announcement\nBoard\nthe board of directors of the Company;\nBusiness Day\na day (other than a Saturday or Sunday) on which commercial banks are open for general business in London, England;\nCircular\nthe circular containing further details of the Fundraise and a notice convening the General Meeting in order to pass the Resolutions, which is expected to be published by the Company on or about 30 December\n2025;\nCompany\nor\nTrellus Health\nTrellus Health\nplc;\nCREST\nthe relevant system (as defined in the CREST Regulations) in\nrespect\nof\nwhich Euroclear is the Operator (as defined in the CREST Regulations);\nCREST Regulations\nthe Uncertificated Securities Regulations 2001 (\nS.I.\n2001\nNo\n3755)\n(as amended);\nDirectors\nor\nBoard\nthe current directors of the Company as at the date of this Announcement;\nEEA\nthe European Economic Area;\nEnlarged Share Capital\nthe entire issued share capital of the Company following assumed conversion of all the Secured Convertible Loan Notes issued to Alumni and exercise of the Warrant;\nEU\nthe European Union;\nEuroclear\nEuroclear UK & International Limited, the\noperator\nof\nCREST;\nExisting Ordinary Shares\nthe 161,508,333\nOrdinary Shares of\n\u00a30.0006 each\nin issue at the date of this document, all of which are admitted to trading on AIM and being the entire issued ordinary share capital of the Company;\nFacility\nthe secured convertible loan note instrument under which the Company proposes to constitute the Secured Convertible Loan Notes and issue them to Alumni;\nFCA\nthe Financial Conduct Authority;\nFSMA\nthe Financial Services and Markets Act 2000\n,\nas amended\n;\nFundraise\nmeans the raising of up to \u00a35 million by way of issue by the Company of the Secured Convertible Loan Notes;\nFundraise\nResolutions\nresolutions 1 and 2 to be proposed at the General Meeting, as set out in the Notice of General Meeting;\nFundraise Shares\nmeans the Ordinary Shares issued to Alumni following conversion of the Secured Convertible Loan Notes;\nGeneral Meeting\nthe general meeting of the Company convened for 9.30 a.m. on 20 January 2026 (or any adjournment thereof) at which the Resolutions will be proposed, notice of which is set out at the end of this document;\nGeneral\nResolutions\nresolutions to be proposed at the General Meeting, further details of which are set out in the notice of General Meeting as contained in the Circular;\nGroup\nthe Company and its subsidiary undertakings (\nand\n\"Group Company\"\nshall be construed accordingly\n);\nISIN\nInternational Securities Identification Number;\nLondon Stock Exchange\nLondon Stock Exchange plc;\nMAR\nRegulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse as it forms part of the law of England and Wales by virtue of section 3 of the European Union (Withdrawal) Act 2018 (as it may be modified from time to time by or under domestic law including, but not limited to, by the Market Abuse (Amendment) (EU Exit) Regulations 2019/310);\nMaterial Adverse Effect\na material adverse effect, or any development or matter likely to have a material adverse effect, in or affecting the business, condition (financial, trading, operational, legal or otherwise), management, properties, assets, rights, results of operations, earnings or assets of the Group, whether or not arising in the ordinary course of business and whether or not foreseeable as at the date of the Placing Agreement;\nMount Sinai\nIcahn School of Medicine at Mount Sinai;\nOrdinary\nShares\nordinary\nshares\nof \u00a30.0006 each in the capital of the Company;\nPost First Tranche Notes\nthe conversion of \u00a3112,500 Secured Convertible Loan Notes into New Ordinary Shares;\nPost Second Tranche Notes\nthe conversion of \u00a3625,000 Secured Convertible Loan Notes into New Ordinary Shares;\nPost Subsequent Tranche Notes\nthe conversion of \u00a3200,000 Secured Convertible Loan Notes into New Ordinary Shares;\nResolutions\ntogether\nthe General\nResolutions and the Fundraise Resolutions\n;\nRIS\nshall have the same meaning as in the AIM Rules;\nSecured Convertible Loan Notes or Notes\nthe secured convertible loan notes to be constituted by the Company pursuant to the Facility in the aggregate principal amount of \u00a35,000,000 plus any interest;\nSCM Advisory\nSinger Capital Markets Advisory LLP, the Company's nominated adviser;\nShareholders\nholders of Ordinary Shares;\nSinger Capital Markets\nSinger Capital Markets Securities Limited, the Company's broker;\nUK MAR\nthe Market Abuse Regulation (EU Regulation No. 596/2014 which forms part of domestic law pursuant to the European Union (Withdrawal) Act 2018);\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCBLBDDLUXDGUG",
          "rns_number": "RNS Number : 1958N"
        },
        {
          "title": "Finance update",
          "announcement_date": "24th Nov 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "24 Nov 2025 07:00\nRNS Number : 6315I\nTrellus Health PLC\n24 November 2025\nThis announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.\u00a0Upon the publication of this announcement, this inside information is now considered to be in the public domain.\nTrellus Health plc\n(\"Trellus Health\", the \"Company\" or the \"Group\")\nFinance update\nLONDON, U.K. AND NEW YORK, U.S. (24\nNovember 2025)\n. Trellus Health\u00ae plc (AIM: TRLS), a healthcare company delivering Trellus Elevate\u00ae, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces it has entered into a unsecured loan agreement with the Company's long standing substantial shareholder, Icahn School of Medicine at Mount Sinai (\"\nMount Sinai\n\"), with a principal amount of US$600,000 (the \"\nLoan Note\n\").\nLoan Note Terms\nThe Loan Note will be non-interest bearing for the first six months. Thereafter, it will accrue interest at an annual rate of 8%, payable in either new ordinary shares of 0.06 pence each (\"\nOrdinary Shares\n\") or cash, at the Company's discretion, upon conversion of the principal amount of the Loan Note.\nThe term of the Loan Note is 12 months, at which point the Company may elect to redeem, convert into Ordinary Shares, or apply a combination of both at a conversion price of 0.525 pence, being the 5-day mid-market price of the Company's shares ending on the business day prior to signing the Loan Note.\nUnder the terms of the Loan Note, any conversion into Ordinary Shares is subject to a cap preventing Mount Sinai from holding more than 29.9% of the Company's issued share capital. This restriction applies to both the principal and any accrued interest.\nCash Runway\nThe proceeds from the Loan Note will support the continued execution of the Company's commercial strategy and extend its near-term cash runway to late January 2026. The Company remains in active discussions regarding a potential equity fundraising to extend the cash runway further. While these discussions are at an advanced stage, there is no guarantee that they will be concluded successfully or within the required timeframe.\nThe Company continues to focus on securing additional commercial contracts with pharmaceutical companies and Contract Research Organizations (\"\nCROs\n\"). Illustrative contract values typically range in total between $500k and $1 million for pharma and between $150k and $500k for CROs, excluding performance incentive fees.\nRelated Party Transaction\nThe Loan Note is deemed to be related party transaction under AIM Rule 13 of the AIM Rules for Companies. Mount Sinai is a substantial shareholder holding 40,384,897 Ordinary Shares equal to 25.0% of the issued share capital of the Company. The Company's Directors (excluding those who are connected to Mount Sinai) consider, having consulted with the Nominated Adviser,\u00a0Singer Capital Markets, that the terms of the related party transaction are fair and reasonable insofar as the shareholders of the Company are concerned.\nDr. Marla Dubinsky, Chief Executive Officer of Trellus Health, said:\n\"\nWe are extremely grateful for Mount Sinai's continued support, which enables us to focus on executing agreements with pharmaceutical companies and CROs. Over the past month, we have signed contracts with two leading global CROs, reaffirming both the value of our offering to the pharmaceutical sector and our ability to secure and deliver on partnerships with industry leaders in drug development and clinical research. We have already begun implementation for the Phase 2B and Phase 3 trials with these partners and expect to launch the initial TrialSet\u2122 programs by year-end.\"\nEnquiries:\nTrellus Health plc\nhttps://trellushealth.com/\nDr. Marla Dubinsky, Chief Executive Officer and Co-Founder\nVia Walbrook PR\nJoy Bessenger, Chief Financial Officer\nSinger Capital Markets\nPhil Davies / Patrick Weaver\nTel: +44 (0)20 7496 3000\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\ntrellus@walbrookpr.com\nPaul McManus / Lianne Applegarth /\nMob: +44 (0)7980 541 893 / +44 (0)7584 391 303/\nAlice Woodings\n+44 (0)7407 804 654\nAbout Trellus Health plc (www.trellushealth.com)\nTrellus Health\u00ae (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.\nTrellus Health\u00ae integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate\u00ae, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying the Trellus Elevate\u00ae methodology resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions and therapeutic areas, Trellus Health\u00ae considers its approach to have potential utility and demand across many conditions.\nThe Company also offers Trellus TrialSet\u2122, a solution for pharmaceutical partners spanning clinical trials to commercialisation, applying the same validated resilience science and platform to support trial success and long-term patient engagement\nThe Company was founded by Icahn School of Medicine at Mount Sinai faculty members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading experts in treating both the physical and emotional impacts of IBD, with a combined 50 years of pioneering whole-person healthcare innovation. Both the founders continue to have a financial interest in the Company.\nShares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit:\nwww.trellushealth.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nUPDPKNBBKBDBODB",
          "rns_number": "RNS Number : 6315I"
        },
        {
          "title": "Contract signed with second leading CRO",
          "announcement_date": "7th Nov 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "7 Nov 2025 07:00\nRNS Number : 5733G\nTrellus Health PLC\n07 November 2025\nTrellus Health plc\n(\"Trellus Health\", the \"Company\" or the \"Group\")\nContract signed with second leading CRO\nLONDON, U.K. AND NEW YORK, U.S. (07 November 2025)\n. Trellus Health\u00ae plc (AIM: TRLS), a healthcare company delivering Trellus Elevate\u00ae, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces it has signed a 12 month contract (the \"Contract\") with one of the largest global clinical research organisations ('CRO's') to utilise its Trellus TrialSet\u2122 offering. The Contract is due to commence before year end, and will focus on immunology and inflammation, supporting recruitment and enrolment optimisation for two late-stage clinical trials.\nThis marks the Company's second contract with a leading CRO, further reinforcing the clinical trials sector as a strategic growth area for Trellus Health\n\u00ae\n. The Trellus TrialSet\u2122 program is designed to enhance clinical trial recruitment by identifying individuals with lower resilience who may be hesitant to enrol and providing structured, evidence-based support to strengthen their resilience and readiness for participation.\nThe Contract, which includes an upfront fee, a monthly management fee, and milestone payments, is structured around three key performance indicators: (i) the number of potential eligible participants opting into the Trellus TrialSet\u2122 program, (ii) the increase in qualified participants referred for screening, and (iii) the reduction in the screen failure rate.\nDr. Marla Dubinsky, Chief Executive Officer of Trellus Health, said:\n\"This represents another important milestone for Trellus Health\u00ae, underscoring the intrinsic value of our Trellus TrialSet\u2122 digital solution and reflecting our continued focus on strategic execution. Since its launch earlier this summer, we have entered into two agreements with leading CROs, validating the relevance and differentiation of our offering. While the contract does not immediately extend the Company's current cash runway beyond early December 2025,\u00a0combined with the Patient Support Program agreement signed with Johnson & Johnson in January 2025 which launched in the spring, these milestones demonstrate the growing recognition of the value Trellus Health delivers to the pharmaceutical sector.\n\"The Company continues to explore options for a potential equity fundraising\u00a0and further updates will be provided in due course, as appropriate.\"\nRegulatory Information\nThis announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.\u00a0Upon the publication of this announcement, this inside information is now considered to be in the public domain.\nEnquiries:\nTrellus Health plc\nhttps://trellushealth.com/\nDr. Marla Dubinsky, Chief Executive Officer and Co-Founder\nVia Walbrook PR\nJoy Bessenger, Chief Financial Officer\nSinger Capital Markets\nJen Boorer / James Todd / Patrick Weaver\nTel: +44 (0)20 7496 3000\nWalbrook PR\nTel: +44 (0)20 7933 8780 or\ntrellus@walbrookpr.com\nPaul McManus / Lianne Applegarth /\nMob: +44 (0)7980 541 893 / +44 (0)7584 391 303/\nAlice Woodings\n+44 (0)7407 804 654\nAbout Trellus Health plc (www.trellushealth.com)\nTrellus Health\u00ae (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.\nTrellus Health\u00ae integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate\u00ae, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying the Trellus Elevate\u00ae methodology resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions and therapeutic areas, Trellus Health\u00ae considers its approach to have potential utility and demand across many conditions.\nThe Company also offers Trellus TrialSet\u2122, a solution for pharmaceutical partners spanning clinical trials to commercialisation, applying the same validated resilience science and platform to support trial success and long-term patient engagement\nThe Company was founded by Icahn School of Medicine at Mount Sinai faculty members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading experts in treating both the physical and emotional impacts of IBD, with a combined 50 years of pioneering whole-person healthcare innovation.\nShares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit:\nwww.trellushealth.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nCNTUPGWWGUPAGMQ",
          "rns_number": "RNS Number : 5733G"
        }
      ],
      "themes": [
        "drilling",
        "operations"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 425,
      "sentiment_breakdown": {
        "positive": 0.0,
        "neutral": 100.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": 0,
      "trend_direction": "flat",
      "intelligence_signal": "DOWNTREND"
    },
    "volatility": {
      "atr_normalized": 8.75,
      "stddev_20d": 0.0
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    },
    "catalyst_dates": {
      "proxy_date": "2026-01-20"
    }
  },
  "ai_insights": {
    "available": false,
    "reason": "LLM module not loaded or analysis failed"
  },
  "crashdash": {
    "industry_intelligence": {
      "category": "INDUSTRIALS",
      "name": "Industrials",
      "icon": "\ud83c\udfed",
      "color": "#64748b",
      "crash_patterns": [
        "Order book decline or cancellations",
        "Margin compression (input costs)",
        "Cyclical demand weakness",
        "Project delays or overruns",
        "Working capital strain"
      ],
      "recovery_paths": [
        "Order book growth or new contracts",
        "Margin recovery (efficiency gains)",
        "Cyclical upturn (capex recovery)",
        "M&A consolidation",
        "Product innovation or new markets"
      ],
      "active_patterns": [],
      "relevant_rns_count": 1,
      "key_metrics": [
        "Order book value (forward revenue)",
        "Book-to-bill ratio",
        "Operating margin trends",
        "Working capital efficiency",
        "Capex cycles (customer industries)"
      ]
    },
    "panic_analysis": {
      "panic_score": 80,
      "signal": "EXTREME_PANIC",
      "interpretation": "\ud83d\udd34 Capitulation zone - contrarian opportunity if fundamentals intact",
      "breakdown": {
        "price_destruction": 40,
        "volume_death": 14,
        "social_silence": 6,
        "news_sentiment": 20
      },
      "is_opportunity": true,
      "opportunity_reason": "\ud83d\udd25 EXTREME PANIC + Intact timing = Prime contrarian entry zone"
    },
    "fear_vs_facts": {
      "fear_points": [
        "\ud83d\udc94 Price destruction: 40/40 points",
        "\ud83d\udcf0 Negative news: 20/20 points"
      ],
      "facts_points": [
        "\ud83d\udcc8 Historical upside: 319% proven capacity"
      ],
      "verdict": "\ud83c\udfaf CONTRARIAN OPPORTUNITY - Fear dominates but facts support recovery potential"
    },
    "crashhunter_signals": [
      {
        "type": "EXTREME_PANIC",
        "icon": "\ud83d\udd34",
        "text": "Panic 80/100",
        "color": "#ef4444"
      },
      {
        "type": "BUILDING",
        "icon": "\ud83d\udcca",
        "text": "Building",
        "color": "#10b981"
      },
      {
        "type": "MODERATE_QUALITY",
        "icon": "\ud83c\udf1f",
        "text": "APEX 57",
        "color": "#3b82f6"
      }
    ],
    "catalyst_pipeline": [
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Result of Meeting",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Grant of Share Options",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Proposed issue of Secured Convertible Loan Notes",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Finance update",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Contract signed with second leading CRO",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Funding announcement or operational update",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Volume expansion confirmation",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      }
    ],
    "decision_matrix": {
      "decision": "BUY",
      "reason": "\ud83c\udfaf CrashHunter Signal: \ud83d\udd25 EXTREME PANIC + Intact timing = Prime contrarian entry zone",
      "checklist": [
        {
          "criterion": "Panic Score",
          "value": "80/100",
          "pass": true,
          "icon": "\ud83d\udd34"
        },
        {
          "criterion": "Timing Regime",
          "value": "EARLY_BUILD",
          "pass": true,
          "icon": "\u2705"
        },
        {
          "criterion": "APEX Quality",
          "value": "57/100",
          "pass": true,
          "icon": "\u2b50"
        },
        {
          "criterion": "Data Confidence",
          "value": "60/100",
          "pass": true,
          "icon": "\ud83c\udfaf"
        },
        {
          "criterion": "Industry Pattern",
          "value": "0 active",
          "pass": true,
          "icon": "\ud83c\udfed"
        }
      ],
      "pass_rate": "5/5"
    },
    "contrarian_panic": {
      "total_score": 38,
      "band": "\ud83d\udfe2 MILD COMPRESSION (Top 50% - WATCHLIST)",
      "components": {
        "compression": {
          "score": 14,
          "max": 40,
          "signals_30d": 2,
          "signals_60d": 3,
          "signals_90d": 3,
          "signals_per_week": 0.23,
          "total_signals": 46,
          "rsi_extreme_count": 3,
          "rsi_ultra_count": 2,
          "escalation_count": 1,
          "density_score": 3,
          "rsi_score": 7,
          "escalation_score": 4,
          "description": "0.2 signals/week | 3 RSI<20 | 1 escalations | \ud83c\udfaf MILD COMPRESSION"
        },
        "intensification": {
          "score": 5,
          "max": 20,
          "recent_types": [
            "CRASH ZONE BOTTOM",
            "EXTREME CRASH BOTTOM",
            "CRASH ZONE BOTTOM"
          ],
          "escalating": false,
          "sustained": false,
          "current_intensity": 1,
          "pattern": "NORMAL CRASH LEVEL"
        },
        "volume_death": {
          "score": 5,
          "max": 15,
          "relative_volume": 2.32,
          "description": "Elevated volume - Some activity"
        },
        "pop_potential": {
          "score": 14,
          "max": 15,
          "best_historical_rally": 692.0,
          "avg_rally": 187.0,
          "signal_count": 46,
          "description": "BIG POPPER - Historical 5x+ (692%)"
        },
        "accumulation": {
          "score": 0,
          "max": 10,
          "has_accumulation": false,
          "bars_since_accum": 0,
          "description": "No accumulation"
        }
      },
      "ticker": "TRLS.L",
      "signal_date": "2026-01-02",
      "total_signals_history": 46
    }
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +11 (AI_Technical_Score=9.0/20)",
      "Drawdown reversion potential: +19 (Drawdown_Pct=92.6%)",
      "Volume confirmation: +10 (Relative_Volume=2.3)",
      "Pattern reliability: +5 (Rally_Count=1.0)",
      "Upside history: +12 (best_rally_pct=319%)"
    ],
    "technical_score": {
      "points": 11,
      "ai_score": 9.0,
      "reason": "AI Technical Score 9.0/20 translates to 11/25 points"
    },
    "drawdown_score": {
      "points": 19,
      "drawdown_pct": 92.59,
      "reason": "Drawdown of 92.6% gives 19/20 points"
    },
    "volume_score": {
      "points": 10,
      "rel_volume": 2.32,
      "reason": "Relative volume 2.32x gives 10 points"
    },
    "pattern_score": {
      "points": 5,
      "rally_count": 1.0,
      "reason": "1.0 historical rallies gives 5/15 points"
    },
    "upside_score": {
      "points": 12,
      "best_rally_pct": 318.75,
      "reason": "Best rally of 319% gives 12/20 points"
    },
    "penalties": {
      "total": 0,
      "items": []
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Early stage positioning offers best R:R if catalysts appear",
        "tag": "MED",
        "evidence": [
          "timing_regime=EARLY_BUILD",
          "current_return_pct=200.0%"
        ]
      },
      {
        "reason": "Proven winner - previously hit lock-in target",
        "tag": "MED",
        "evidence": [
          "lock_in_reached=True"
        ]
      }
    ],
    "reasons_to_sell": []
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Watch / Starter",
      "action": "Wait for base + catalyst confirmation; starter position only",
      "sizing": "0-1% until CONFIRMED",
      "risk": "Invalidation = breaks recent lows / dilution / suspension",
      "profit_taking": "Scale out 25% at +15%, 25% at +50%, runner above"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "EARLY_BUILD",
    "run_multiple": 0.63,
    "current_run_pct": 200.0,
    "avg_historical_run_pct": 318.75
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows EARLY_BUILD timing with 57/100 APEX score. Historical data shows 1 rallies averaging 319% upside. Current position: +200.0%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.",
    "bull_case": [
      "Early regime often offers best risk/reward"
    ],
    "bear_case": [
      "Monitor for breakdown signals"
    ],
    "timing_translation": "Early accumulation phase. Watch for confirmation before committing size.",
    "confidence_explained": "Confidence 60/100 reflects full data quality with triangulation loaded."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": true,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": false
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  }
}